India’s IPCA Gets U.S. Clearance For Migraine Generic
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has cleared a generic blood-pressure drug made by Indian Pharmaceuticals Combine Association. Marketing approval allows IPCA to produce its generic of Wyeth's Inderide (propranolol hydrochloride) tablets for treating migraine headaches, a $24.1 million-a-year product. IPCA already makes and markets its drugs in 100 countries, with exports accounting for half of its business. (Click here for more